Crinetics Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRNX) $33.50 +0.27 (+0.81%) (As of 02:09 PM ET) Add Compare Share Share Today's Range$32.82▼$33.6550-Day Range$25.62▼$33.5052-Week Range$15.23▼$34.09Volume193,054 shsAverage Volume769,292 shsMarket Capitalization$2.24 billionP/E RatioN/ADividend YieldN/APrice Target$44.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Crinetics Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.7% Upside$44.38 Price TargetShort InterestHealthy9.28% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.32Based on 6 Articles This WeekInsider TradingSelling Shares$6.68 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.66) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.63 out of 5 starsMedical Sector119th out of 958 stocksPharmaceutical Preparations Industry29th out of 396 stocks 4.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.38, Crinetics Pharmaceuticals has a forecasted upside of 34.7% from its current price of $32.95.Amount of Analyst CoverageCrinetics Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.28% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently decreased by 7.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 2.4 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Crinetics Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest7 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,676,966.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($3.66) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -9.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -9.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.Read More CRNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Stock News HeadlinesDecember 6, 2023 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Reaffirmed by Cantor FitzgeraldDecember 4, 2023 | benzinga.comCrinetics Pharmaceuticals Stock (NASDAQ:CRNX) Insider TradesDecember 7, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. December 4, 2023 | benzinga.comCrinetics Pharmaceuticals Stock (NASDAQ:CRNX) Dividends: History, Yield and DatesDecember 3, 2023 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $44.38 Consensus PT from BrokeragesNovember 28, 2023 | seekingalpha.comCrinetics Pharmaceuticals: Some Caution WarrantedNovember 20, 2023 | finance.yahoo.comCrinetics Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 20, 2023 | finance.yahoo.comCrinetics Pharmaceuticals to Participate in Upcoming Investor ConferencesDecember 7, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. November 20, 2023 | markets.businessinsider.com8 Analysts Have This to Say About Crinetics PharmaceuticalsNovember 17, 2023 | finance.yahoo.comBillionaire Steve Cohen Goes Big on These 2 ‘Strong Buy’ Stocks — Here’s Why You Should FollowNovember 11, 2023 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 10, 2023 | finance.yahoo.comCrinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 10, 2023 | markets.businessinsider.comPositive Outlook on Crinetics Pharmaceuticals: Leland Gershell’s Analysis of Clinical Programs and Financial StabilityNovember 9, 2023 | finance.yahoo.comCrinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial GrowthNovember 8, 2023 | markets.businessinsider.comBuy Rating for Crinetics Pharmaceuticals: Promising Future with Upcoming Phase 3 PATHFNDR-2 Data and Strong Financial PositionNovember 8, 2023 | finance.yahoo.comHere's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price StrengthNovember 8, 2023 | finance.yahoo.comWall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High?November 7, 2023 | finance.yahoo.comCrinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 4, 2023 | finance.yahoo.comInsider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)October 26, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)October 24, 2023 | markets.businessinsider.com11 Analysts Have This to Say About Crinetics PharmaceuticalsOctober 23, 2023 | finance.yahoo.comWhat Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing'October 23, 2023 | finance.yahoo.comWall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a BetOctober 20, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Alan Krasner Sells 7,000 Shares of Crinetics Pharmaceuticals IncOctober 6, 2023 | finance.yahoo.comSwelling losses haven't held back gains for Crinetics Pharmaceuticals (NASDAQ:CRNX) shareholders since they're up 58% over 3 yearsOctober 5, 2023 | msn.comCrinetics Pharmaceuticals (CRNX) Price Target Increased by 7.25% to 49.47See More Headlines Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$44.38 High Stock Price Target$56.00 Low Stock Price Target$33.00 Potential Upside/Downside+33.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,920,000.00 Net Margins-4,223.27% Pretax Margin-4,202.16% Return on Equity-57.04% Return on Assets-49.83% Debt Debt-to-Equity RatioN/A Current Ratio14.23 Quick Ratio14.23 Sales & Book Value Annual Sales$4.74 million Price / Sales468.30 Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book5.65Miscellaneous Outstanding Shares66,800,000Free Float62,123,000Market Cap$2.22 billion OptionableNot Optionable Beta0.55 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 61)Founder, President, CEO & Director Comp: $870.69kDr. Stephen F. Betz Ph.D. (Age 57)Founder & Chief Scientific Officer Comp: $618.58kMr. Marc J. C. Wilson (Age 44)Chief Financial Officer Comp: $585.54kMr. James Hassard (Age 57)Chief Commercial Officer Comp: $513.34kDr. Dana Pizzuti M.D. (Age 67)Chief Development Officer Comp: $493.62kMr. Jeff E. Knight (Age 52)Chief Operating Officer Comp: $237.64kMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerDr. Alan S. Krasner M.D. (Age 60)Chief Medical Officer Comp: $571.97kMr. Kevin CappsHead of Intellectual PropertyMore ExecutivesKey CompetitorsSchrödingerNASDAQ:SDGRRocket PharmaceuticalsNASDAQ:RCKTRhythm PharmaceuticalsNASDAQ:RYTMTG TherapeuticsNASDAQ:TGTXCymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 28,388 shares on 12/6/2023Ownership: 0.125%Wellington Management Group LLPBought 38,523 shares on 12/1/2023Ownership: 5.449%American Century Companies Inc.Bought 9,925 shares on 11/30/2023Ownership: 0.044%Stephen F BetzSold 3,000 sharesTotal: $95,520.00 ($31.84/share)Deutsche Bank AGBought 7,125 shares on 11/24/2023Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions CRNX Stock Analysis - Frequently Asked Questions Should I buy or sell Crinetics Pharmaceuticals stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks. What is Crinetics Pharmaceuticals' stock price target for 2024? 9 equities research analysts have issued 12 month price objectives for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $33.00 to $56.00. On average, they anticipate the company's stock price to reach $44.38 in the next year. This suggests a possible upside of 34.7% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts. How have CRNX shares performed in 2023? Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 80.1% and is now trading at $32.95. View the best growth stocks for 2023 here. Are investors shorting Crinetics Pharmaceuticals? Crinetics Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 6,200,000 shares, a drop of 7.6% from the October 31st total of 6,710,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is currently 4.0 days. View Crinetics Pharmaceuticals' Short Interest. When is Crinetics Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CRNX earnings forecast. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.12. The firm had revenue of $0.35 million for the quarter. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 57.04% and a negative net margin of 4,223.27%. What ETF holds Crinetics Pharmaceuticals' stock ? iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio. What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC). When did Crinetics Pharmaceuticals IPO? (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.45%), FMR LLC (3.20%), Jennison Associates LLC (2.62%), Eventide Asset Management LLC (1.53%), Avidity Partners Management LP (0.91%) and Northern Trust Corp (0.89%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CRNX) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.